Clinical Trials · NCT07441252
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Amgen
- Enrollment
- 180
- Start date
- Mar 2026
- Locations
- 23 sites, United States
- Primary endpoint
- Percent Change from Baseline in Liver Fat Content by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) at Week 52